ArticleEndocrine connections2025
Microwave ablation for small papillary thyroid carcinomas: clinical outcomes and thyroid function preservation.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study explores the impact of microwave ablation (MWA) on thyroid function in patients with small papillary thyroid carcinomas (SPTCs) using a specific energy/volume model to optimize treatment and evaluate clinical efficacy. Methods: A cohort of 70 patients with confirmed SPTCs underwent MWA tailored to individual nodule characteristics. Pre- and post-ablation assessments included ultrasound imaging for nodule size and thyroid function tests (thyroid-stimulating hormone, free thyroxine and free triiodothyronine levels) were conducted at baseline, 1, 3, 6 and 12 months post-treatment. The main results are the complete ablation rate of nodules and the stability of thyroid function after treatment. Secondary outcomes include the incidence of complications and other clinical parameters. Results: The complete ablation rate was achieved in 95% of the nodules, with most patients (90%) requiring a single ablation session. Nodule size reduced significantly from an average of 174.0 ± 259.1 to 3.2 ± 11.3 mm3, with a mean volume reduction rate of 98.47 (5.82%) at the 18-month follow-up. Stable thyroid function and minimal fluctuations in hormone levels were observed in 90% of patients, demonstrating the effectiveness of MWA in preserving thyroid function. Notably, lower energy/volume ratios were linked to a reduced risk of complications and preservation of thyroid function. Only 5% of patients reported minor complications, with no major adverse events. Conclusions: The study's results validate the clinical utility of MWA in energy/volume setting as an effective, minimally invasive treatment for SPTCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.